Norges Bank Buys New Position in Insulet Corporation $PODD

Norges Bank bought a new stake in Insulet Corporation (NASDAQ:PODD) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,058,238 shares of the medical instruments supplier’s stock, valued at approximately $300,794,000. Norges Bank owned about 1.50% of Insulet at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Glenmede Investment Management LP boosted its holdings in Insulet by 1.6% in the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after acquiring an additional 35 shares during the last quarter. Curi Capital LLC boosted its holdings in Insulet by 0.8% in the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after acquiring an additional 36 shares during the last quarter. WINTON GROUP Ltd boosted its holdings in Insulet by 0.9% in the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock valued at $1,261,000 after acquiring an additional 37 shares during the last quarter. Camarda Financial Advisors LLC lifted its stake in Insulet by 0.5% in the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after buying an additional 40 shares during the period. Finally, Larson Financial Group LLC lifted its stake in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares during the period.

Insulet Price Performance

Shares of PODD opened at $142.43 on Wednesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. Insulet Corporation has a 52-week low of $140.63 and a 52-week high of $354.88. The business’s 50 day moving average price is $181.94 and its two-hundred day moving average price is $243.52. The firm has a market cap of $9.86 billion, a PE ratio of 33.12, a price-to-earnings-growth ratio of 1.17 and a beta of 1.13.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same period in the prior year, the firm earned $1.02 earnings per share. Insulet’s revenue for the quarter was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities analysts anticipate that Insulet Corporation will post 6.44 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on PODD shares. Wells Fargo & Company dropped their price target on Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. BTIG Research dropped their price target on Insulet from $260.00 to $235.00 and set a “buy” rating on the stock in a research note on Tuesday, May 26th. Leerink Partners dropped their price target on Insulet from $360.00 to $247.00 in a research note on Thursday, May 7th. William Blair started coverage on Insulet in a research note on Wednesday, May 20th. They issued an “outperform” rating on the stock. Finally, Truist Financial dropped their price target on Insulet from $315.00 to $250.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Twenty-one investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $252.04.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.